- Home
- PLRX vs MGNX Comparison
PLRX vs MGNX Comparison
Compare PLRX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- MGNX
- Stock Information
- Founded
- PLRX 2015
- MGNX 2000
- Country
- PLRX United States
- MGNX United States
- Employees
- PLRX N/A
- MGNX N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- MGNX Health Care
- Exchange
- PLRX Nasdaq
- MGNX Nasdaq
- Market Cap
- PLRX 84.7M
- MGNX 87.7M
- IPO Year
- PLRX 2020
- MGNX 2013
- Fundamental
- Price
- PLRX $1.28
- MGNX $1.33
- Analyst Decision
- PLRX Hold
- MGNX Hold
- Analyst Count
- PLRX 10
- MGNX 9
- Target Price
- PLRX $9.79
- MGNX $5.33
- AVG Volume (30 Days)
- PLRX 950.8K
- MGNX 2.0M
- Earning Date
- PLRX 08-06-2025
- MGNX 08-05-2025
- Dividend Yield
- PLRX N/A
- MGNX N/A
- EPS Growth
- PLRX N/A
- MGNX N/A
- EPS
- PLRX N/A
- MGNX N/A
- Revenue
- PLRX N/A
- MGNX $154,050,000.00
- Revenue This Year
- PLRX N/A
- MGNX N/A
- Revenue Next Year
- PLRX N/A
- MGNX N/A
- P/E Ratio
- PLRX N/A
- MGNX N/A
- Revenue Growth
- PLRX N/A
- MGNX 255.31
- 52 Week Low
- PLRX $1.10
- MGNX $0.99
- 52 Week High
- PLRX $16.10
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- PLRX 36.66
- MGNX 41.45
- Support Level
- PLRX $1.56
- MGNX $1.33
- Resistance Level
- PLRX $1.70
- MGNX $2.17
- Average True Range (ATR)
- PLRX 0.12
- MGNX 0.17
- MACD
- PLRX -0.02
- MGNX -0.02
- Stochastic Oscillator
- PLRX 5.68
- MGNX 2.38
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.